NI201000231A - Inhibidores de ciclopropil polimerasa. - Google Patents

Inhibidores de ciclopropil polimerasa.

Info

Publication number
NI201000231A
NI201000231A NI201000231A NI201000231A NI201000231A NI 201000231 A NI201000231 A NI 201000231A NI 201000231 A NI201000231 A NI 201000231A NI 201000231 A NI201000231 A NI 201000231A NI 201000231 A NI201000231 A NI 201000231A
Authority
NI
Nicaragua
Prior art keywords
hydrogen
alkyl
compounds
formula
cyclopropyl
Prior art date
Application number
NI201000231A
Other languages
English (en)
Inventor
Hugo María Jonckers Tim
Vandyck Koen
Jean-Marie Bernard Raboisson Pierre
Original Assignee
Centocor Ortho Biotech Products L P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41095413&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201000231(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centocor Ortho Biotech Products L P filed Critical Centocor Ortho Biotech Products L P
Publication of NI201000231A publication Critical patent/NI201000231A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

Los compuestos de la fórmula I: donde: R2 es hidrógeno o alquilo C1-C4; R3 y R4 son hidrógeno, -C(=0)R5, o - C(=0)CHR6-NH2; o R3 es hidrógeno y R4 es un éster de monofosfato, difosfato, o trifosfato; o R3 es hidrógeno, - C(=0)CHR5, o -C(=0)CHR6-NH2 y R4 es (fórmula 2) cada R5 es hidrógeno, alquilo C1-C6 o cicloalquilo C3-C7; R6 es hidrógeno o alquilo C1-C6; R7 es fenilo opcionalmente sustituido; naftilo; o indolilo; R8 y R8 son hidrógeno, alquilo C1- C6, bencilo; o R8 y R8 combinados forman cicloalquilo C3-C7; R9 es alquilo C1-C6, bencilo; o fenilo opcionalmente sustituido; siempre que R2, R3 y R4 no sean todos hidrógeno; o su sal o solvato aceptable para uso farmacéutico; formulaciones farmacéuticas con los compuestos I; el uso de compuestos I, incluyendo los compuestos de fórmula I donde R2, R3 y R4 son todos hidrógeno, como inhibidores del VHC.
NI201000231A 2008-07-01 2010-12-23 Inhibidores de ciclopropil polimerasa. NI201000231A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08159396 2008-07-01
EP08171005 2008-12-08

Publications (1)

Publication Number Publication Date
NI201000231A true NI201000231A (es) 2011-09-03

Family

ID=41095413

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000231A NI201000231A (es) 2008-07-01 2010-12-23 Inhibidores de ciclopropil polimerasa.

Country Status (29)

Country Link
US (1) US8431588B2 (es)
EP (1) EP2141172B1 (es)
JP (1) JP5624029B2 (es)
KR (1) KR20110038683A (es)
CN (2) CN105693794A (es)
AP (1) AP2010005505A0 (es)
AR (1) AR072428A1 (es)
AU (1) AU2009266004B2 (es)
BR (1) BRPI0913643A2 (es)
CA (1) CA2729316A1 (es)
CL (1) CL2010001634A1 (es)
CO (1) CO6321255A2 (es)
DK (1) DK2141172T3 (es)
EA (1) EA022754B1 (es)
EC (1) ECSP10010725A (es)
ES (1) ES2396803T3 (es)
HK (1) HK1226080A1 (es)
HR (1) HRP20121068T1 (es)
IL (1) IL209932A (es)
MX (1) MX2010014493A (es)
NI (1) NI201000231A (es)
PL (1) PL2141172T3 (es)
PT (1) PT2141172E (es)
SI (1) SI2141172T1 (es)
SV (1) SV2010003779A (es)
TW (1) TW201012814A (es)
UY (1) UY31950A (es)
WO (1) WO2010000459A1 (es)
ZA (1) ZA201009294B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102089887B1 (ko) * 2008-09-08 2020-03-16 사우디 아람코 테크놀로지스 컴퍼니 폴리카보네이트 폴리올 조성물
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5845841B2 (ja) 2011-11-18 2016-01-20 東芝ライテック株式会社 照明制御装置
AU2013221571A1 (en) 2012-02-14 2014-08-28 University Of Georgia Research Foundation, Inc. Spiro [2.4] heptanes for treatment of Flaviviridae infections
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
IL295418B2 (en) 2015-03-06 2023-10-01 Atea Pharmaceuticals Inc Cell-D-2'-deoxy-2'-alpha-fluoro-2'-cell-C-modified-2-different-N6-purine modified nucleotides for the treatment of hepatitis C virus
RU2590952C1 (ru) * 2015-05-26 2016-07-10 Вячеслав Энгельсович Семёнов Средство гепатопротекторного действия
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
PT3512863T (pt) 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
KR102335193B1 (ko) 2017-02-01 2021-12-03 아테아 파마슈티컬즈, 인크. C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100333016B1 (ko) 1992-12-29 2002-11-22 아보트 러보러터리즈 레트로바이러스성프로테아제억제화합물,이의제조방법및이를함유하는약제학적조성물
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
DE14169110T1 (de) 2002-06-28 2022-05-12 Centre National De La Recherche Scientifique -Cnrs- Modifizierte 2'- und 3'-Nukleosid-Prodrugs zur Behandlung von Flaviridae-Infektionen
CA2523083C (en) * 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
CA2577526A1 (en) * 2004-08-23 2006-03-02 Joseph Armstrong Martin Antiviral 4'-azido-nucleosides
JP2010505902A (ja) * 2006-10-10 2010-02-25 メディヴィル・アクチエボラーグ Ｈｃｖヌクレオシド阻害剤

Also Published As

Publication number Publication date
AU2009266004A1 (en) 2010-01-07
EP2141172B1 (en) 2012-10-24
CO6321255A2 (es) 2011-09-20
CN105693794A (zh) 2016-06-22
EA022754B1 (ru) 2016-02-29
HRP20121068T1 (hr) 2013-01-31
CN102083845A (zh) 2011-06-01
EP2141172A1 (en) 2010-01-06
TW201012814A (en) 2010-04-01
SI2141172T1 (sl) 2013-02-28
AP2010005505A0 (en) 2010-12-31
AR072428A1 (es) 2010-08-25
PL2141172T3 (pl) 2013-03-29
DK2141172T3 (da) 2013-01-21
PT2141172E (pt) 2013-01-14
JP5624029B2 (ja) 2014-11-12
KR20110038683A (ko) 2011-04-14
WO2010000459A1 (en) 2010-01-07
JP2011526270A (ja) 2011-10-06
MX2010014493A (es) 2011-05-19
HK1226080A1 (zh) 2017-09-22
CL2010001634A1 (es) 2011-08-05
IL209932A (en) 2013-12-31
ZA201009294B (en) 2012-06-27
BRPI0913643A2 (pt) 2015-11-24
SV2010003779A (es) 2011-02-08
CA2729316A1 (en) 2010-01-07
ECSP10010725A (es) 2011-04-29
US8431588B2 (en) 2013-04-30
UY31950A (es) 2010-01-29
IL209932A0 (en) 2011-02-28
AU2009266004B2 (en) 2014-01-30
US20110092460A1 (en) 2011-04-21
ES2396803T3 (es) 2013-02-27
CN102083845B (zh) 2016-09-14
EA201170118A1 (ru) 2011-06-30

Similar Documents

Publication Publication Date Title
NI201000231A (es) Inhibidores de ciclopropil polimerasa.
UY32308A (es) Nucleótidos uracil ciclopropílicos
ECSP11011461A (es) Espironucleósidos uracílicos oxetánicos
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR083676A1 (es) Compuestos heterociclicos, útiles como inhibidores de quinasa y composiciones farmaceuticas que los contienen
ECSP109932A (es) Compuestos de biciclolactama sustituida
CO6210729A2 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
CU20080165A7 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR072803A1 (es) Tetrahidrocinolinas como inhibidores de la 11- beta -hsd1 para la diabetes
AR110753A1 (es) Inhibidores selectivos de jak1
AR090557A1 (es) DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
UY32635A (es) Derivados de bis-(sulfonilamino) en terapia 735
ECSP22027784A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
AR088414A1 (es) Derivados sustituidos de indol
AR085542A1 (es) Compuestos de azaespirodecanona como inhibidores de hsl
AR098854A1 (es) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas
AR089361A1 (es) Derivados de quinolina como inhibidores de la enzima pde10a
TH112183B (th) สารยับยั้งไซโคลโพรพิล พอลิเมอเรส
AR098583A1 (es) Compuesto de sulfonamida de benzotiofeno, composición farmacéutica que lo comprende y su uso para la preparación de dicha composición
AR108805A1 (es) Derivados de pirimidina como inhibidores de lrrk2